Vivus Obesity Pill Scores With Phase III Data, But Still Faces Market Hurdles
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With complete Phase III results for its obesity drug Qnexa in hand, Vivus has aced one important test on the road to commercialization. But other major hurdles remain - including passing regulatory muster and convincing a partner to sign up to back a drug that combines generic pills
You may also be interested in...
Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin
New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval
Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin
New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval
Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’
Several anti-obesity treatments are in the home stretch of late-stage development, promising to rev up a stagnant market and satisfy pent-up demand. But there's an elephant in the weight loss room - nobody seems to know who will pick up the tab for new drugs